Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of safinamide 100 mg as add-on therapy in idiopathic Parkinson's disease with motor fluctuations
2014-002600-24Phase 3Completed
- Sponsor
- Zambon
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Safinamide 100 mg once daily add-on with Placebo once daily add-on (2 arms). Primary endpoint: Change in daily OFF time from baseline to endpoint. Started Jul 2015; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-002600-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002600-24.